Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation

A method for treating a subject with cancer, comprising:

• administering to the subject a therapeutically effective amount of an anti-CD44-IR700 molecule;
• irradiating the subject and/or irradiating cancer cells in the subject at a wavelength of 660 to 740 nm and at a dose of at least 1 J/cm2;
• and
• administering to the subject a therapeutically effective amount of an anti-PD-1 antibody, an anti-PD-L1 antibody, or both,
• wherein the anti-CD44-IR700 molecule and the anti-PD-1 antibody, an anti-PD-L1 antibody, or both, are administered sequentially or concurrently, and wherein the anti-CD44-IR700 molecule is administered prior to the irradiating step,
• thereby treating the subject with cancer.

A method for treating a subject with cancer, comprising:

• administering to the subject a therapeutically effective amount of an anti-CD44-IR700 molecule;
• administering to the subject a therapeutically effective amount of an anti-CD25-IR700 molecule;
• and
• irradiating the subject and/or irradiating cancer cells in the subject at a wavelength of 660 to 740 nm and at a dose of at least 1 J/cm2;
• wherein the anti-CD44-IR700 molecule and the anti-CD25-IR700 molecule are administered sequentially or concurrently, and wherein the anti-CD44-IR700 molecule and the CD25-IR700 molecule are administered prior to the irradiating step, thereby treating the subject with cancer.

A method of producing memory T cells, comprising:

• administering to a subject a therapeutically effective amount of one or more antibody-IR700 molecules, wherein the antibody specifically binds to a tumor-specific protein on the surface of a cancer cell;
• irradiating the subject and/or irradiating cells in the subject at a wavelength of 660 to 740 nm and at a dose of at least 1 J/cm2;
• and
• administering to the subject a therapeutically effective amount of one or more immunomodulators,
• wherein the one or more antibody-IR700 molecules and the one or more immunomodulators are administered sequentially or concurrently, and wherein the one or more antibody-IR700 molecule is administered prior to the irradiating step,
• thereby producing memory T cells.

A method of killing a cancer cell in a subject's blood, comprising:

• administering to the subject a therapeutically effective amount of one or more antibody-IR700 molecules, wherein the antibody specifically binds to a tumor-specific protein on the surface of a cancer cell;
• irradiating the cancer cell with a NIR LED at a wavelength of 660 to 740 nm at a dose of at least 20 J/cm2, wherein the NIR LED is present in a wearable device worn by the subject;
• and
• administering to the subject an effective amount of one or more immunomodulators,
• wherein the one or more antibody-IR700 molecules and the one or more immunomodulators are administered sequentially or concurrently, and wherein the one or more antibody-IR700 molecule is administered prior to the irradiating step,
• thereby killing the cancer cell.